Compare PPG Industries, Inc. (PPG) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PPG Industries, Inc. vs Regeneron Pharmaceuticals Inc — how do they compare? PPG Industries, Inc. trades at $105.43 (market cap $23.36B), while Regeneron Pharmaceuticals Inc trades at $739.58 (market cap $76.40B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 3.3× PPG Industries, Inc.'s market cap, and PPG Industries, Inc. pays the higher dividend (2.82%). Which is the better fit depends on your goals — on Pluang, investors hold PPG Industries, Inc. for 68 Days and Regeneron Pharmaceuticals Inc for 107 Days on average.
| PPG | REGN | |
|---|---|---|
Market Cap | $23.36B | $76.40B |
Volume | 1,972,399 | 626,381 |
Sector | Basic Materials | Health |
52-Week High | $131.56 | $852.03 |
52-Week Low | $94.34 | $557.73 |
Typical Hold Time | 68 Days | 107 Days |
Enterprise Value | $29.22B | $71.12B |
Dividend Yield | 2.82% | 0.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPG trades at $105.45, down 1.02% on the day, with a bearish technical signal from moving averages. The stock shows mixed earnings performance, missing Q4 2025 and Q2 2026 estimates but beating in Q1 2026. Fundamentals are solid with a P/E of 15.08, net income margin of 9.57%, and strong cash flow generation of $1.94B from operations in 2025. Recent news highlights margin pressures in the Automotive Refinish segment and upcoming Q3 2026 earnings on October 27.
The outlook is cautiously optimistic given analyst consensus favoring Buy with a $130 price target, implying 23% upside. Key opportunities include earnings growth and dividend stability, while risks involve segment-specific weakness and macroeconomic headwinds affecting demand. The stock's current valuation near support levels may attract value investors awaiting clearer earnings momentum.
Regeneron Pharmaceuticals (REGN) trades at $739.57, up 0.12% on the day, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company maintains robust profitability with a net income margin of 27.86%. A major $8 billion expansion of the immunology alliance with Sanofi, announced October 1, 2026, provides significant future revenue potential and strategic momentum.
The outlook is positive, supported by strong earnings, a lucrative partnership, and a consensus analyst price target of $846. Key risks include competitive pressures in key drug markets and reliance on successful clinical trial outcomes. The stock presents a compelling opportunity for growth investors, though volatility may persist near-term.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About PPG Industries, Inc.
PPG is a global producer of coatings. The company is the world's largest producer of coatings after the purchase of selected Akzo Nobel assets. PPG's products are sold to a wide variety of end users, including the automotive, aerospace, construction, and industrial markets. The company has a footprint in many regions around the globe, with less than half of sales coming from North America in recent years. PPG is focused on its coatings and specialty products and expansion into emerging regions, as exemplified by the Comex acquisition.
Read more on PPG →About Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →
